Clinical trialNCT00705874CompletedPhase 1Interventional

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

SponsorProgen PharmaceuticalsEnrollment172Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047 will be escalated until the maximum tolerated dose is established.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Joe Stephenson, MD
Cancer Centres of the Carolinas, Greenville, SC 29605
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Rocky Mountain Cancer Centre
Denver, Colorado, United States
Cancer Centres of Florida
Ocoee, Florida, United States
Central Indiana Cancer Centres
Indianapolis, Indiana, United States
Comprehensive Cancer Centres of Nevada
Las Vegas, Nevada, United States
New York Oncology Hematology Pc
Albany, New York, United States
Dayton Oncology and Hematology, Pa
Kettering, Ohio, United States
Cancer Centres of the Carolinas
Greenville, South Carolina, United States
Texas Oncology, Pa
Dallas, Texas, United States
Tyler Cancer Centre
Tyler, Texas, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Northwest Cancer Specialists - Vancouver Cancer Centre
Vancouver, Washington, United States
North Star Lodge Cancer Centre
Yakima, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CGC-11047 and 5-flurouracil / leucovorinCGC-11047 and bevacizumabCGC-11047 and cisplatinCGC-11047 and docetaxelCGC-11047 and erlotinibCGC-11047 and gemcitabineCGC-11047 and sunitinib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2006
Primary completion: 31 Aug 2011
Completion: 30 Sept 2011
Last update posted: 21 Jul 2016
Registered enrollment: 172
Registry id: NCT00705874

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.